Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients

被引:103
|
作者
Inaba, M.
Okuno, S.
Imanishi, Y.
Yamada, S.
Shioi, A.
Yamakawa, T.
Ishimura, E.
Nishizawa, Y.
机构
[1] Osaka City Univ, Grad Sch Med, Dept Endocrinol Metab & Mol Med, Abeno Ku, Osaka 5458585, Japan
[2] Osaka City Univ, Grad Sch Med, Dept Nephrol, Abeno Ku, Osaka 5458585, Japan
[3] Shirasagi Hosp Kidney Ctr, Osaka, Japan
关键词
FGF-23; hemodialysis; phosphate; type; 2; diabetes; vascular calcification;
D O I
10.1007/s00198-006-0154-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Fibroblast growth factor (FGF) 23 is a recently identified circulating factor that regulates phosphate (Pi) metabolism. Since the derangement of Pi control is an important risk factor for vascular calcification, we investigated the importance of plasma FGF-23 in the development of vascular calcification in the aorta and peripheral artery in hemodialysis patients with and without diabetes mellitus (DM). Methods: Male hemodialysis patients with DM (n=32) and without DM (n=56) were examined. Plasma samples were obtained before the start of dialysis sessions, and the FGF-23 levels were determined by enzyme-linked immunosorbent assay. Roentgenography of the aorta and hand artery was performed, and visible vascular calcification was evaluated by one examiner, who was blinded to the patient characteristics. Results: In the 56 non-DM hemodialysis patients, vascular calcification was found in the hand artery in 5 patients (8.9%) and in the aorta in 23 patients (41.1%). These levels were significantly lower (p < 0.05) than in the 32 DM patients, of whom, 19 (59.4%) and 21 (65.6%) had vascular calcification of the hand artery and aorta, respectively. Multiple regression analyses performed separately in the non-DM and DM patients showed that the plasma FGF-23 level, CaxPi product, and body weight are independent factors significantly associated with hand-artery calcification and that diastolic blood pressure is associated with aorta calcification in non-DM patients. In DM patients, the plasma FGF-23 level and hemodialysis duration emerged as independent factors associated with hand-artery calcification and diastolic blood pressure was associated with aorta calcification. The independent association of the plasma FGF-23 level with hand-artery calcification was retained in both non-DM and DM patients when adjusted for the CaxPi product. Conclusions: Our findings show that the plasma FGF-23 level is an independent factor negatively associated with peripheral vascular calcification in the hand artery, but not in the aorta, in both male non-DM and DM hemodialysis patients, even when adjusted for the CaxPi product. This study raises the possibility that the plasma FGF-23 level may provide a reliable marker for Moenckeberg's medial calcification in male hemodialysis patients, independent of its regulatory effect on Pi metabolism.
引用
收藏
页码:1506 / 1513
页数:8
相关论文
共 50 条
  • [1] Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients
    M. Inaba
    S. Okuno
    Y. Imanishi
    S. Yamada
    A. Shioi
    T. Yamakawa
    E. Ishimura
    Y. Nishizawa
    [J]. Osteoporosis International, 2006, 17 : 1506 - 1513
  • [2] Serum Fibroblast Growth Factor-23 Levels and Progression of Aortic Arch Calcification in Non-Diabetic Patients on Chronic Hemodialysis
    Tamei, Noriko
    Ogawa, Tetsuya
    Ishida, Hideki
    Ando, Yoshitaka
    Nitta, Kosaku
    [J]. JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2011, 18 (03) : 217 - 223
  • [3] Plasma levels of fibroblast growth factor-23 and mineral metabolism in diabetic and non-diabetic patients on chronic hemodialysis
    Fumiko Kojima
    Keiko Uchida
    Tetsuya Ogawa
    Yoshiko Tanaka
    Kosaku Nitta
    [J]. International Urology and Nephrology, 2008, 40 : 1067 - 1074
  • [4] Plasma levels of fibroblast growth factor-23 and mineral metabolism in diabetic and non-diabetic patients on chronic hemodialysis
    Kojima, Fumiko
    Uchida, Keiko
    Ogawa, Tetsuya
    Tanaka, Yoshiko
    Nitta, Kosaku
    [J]. INTERNATIONAL UROLOGY AND NEPHROLOGY, 2008, 40 (04) : 1067 - 1074
  • [5] Fibroblast Growth Factor-23 importance as a prognostic factor in hemodialysis patients
    Al Atbee, Mohammed Younus Naji
    Hamu, Ali Hussein
    Hammoudi, Faten Abdulghani
    Allawi, Ali Abdulmajid Dyab
    Tuama, Hala Sami
    [J]. REVISTA LATINOAMERICANA DE HIPERTENSION, 2023, 18 (09): : 423 - 431
  • [6] A Study on Diabetic Patients Related To Functions of Fibroblast Growth Factor-23 on Bone Metabolism
    Suwalka, Abhilasha
    Sharma, Balram
    Prabhakar, Pranav Kumar
    [J]. JOURNAL OF PHARMACEUTICAL NEGATIVE RESULTS, 2022, 13 : 1008 - 1022
  • [7] VASCULAR ACCESS SURVIVAL IN DIABETIC AND NON-DIABETIC HEMODIALYSIS-PATIENTS
    AMAN, LC
    LEVIN, NW
    DUMLER, F
    SMITH, DW
    [J]. KIDNEY INTERNATIONAL, 1982, 21 (01) : 162 - 162
  • [8] ASSOCIATION BETWEEN FIBROBLAST GROWTH FACTOR-23 AND VASCULAR CALCIFICATION IN ATHLETIC PATIENTS: A META-ANALYSIS
    Luo, Yan-Kun
    Liu, Huan
    Chen, Ye
    Li, Rong-Shan
    Zhou, Yun
    [J]. REVISTA INTERNACIONAL DE MEDICINA Y CIENCIAS DE LA ACTIVIDAD FISICA Y DEL DEPORTE, 2024, 24 (95): : 524 - 537
  • [9] The Association between Fibroblast Growth Factor-23 and Vascular Calcification Is Mitigated by Inflammation Markers
    NasrAllah, Mohamed M.
    El-Shehaby, Amal R.
    Osman, Noha A.
    Fayad, Tarek
    Nassef, Amr
    Salem, Mona M.
    El Din, Usama A. A. Sharaf
    [J]. NEPHRON EXTRA, 2013, 3 (01): : 106 - 112
  • [10] Fibroblast growth factor-23 is associated with imaging markers of diabetic cardiomyopathy and anti-diabetic therapeutics
    Sorensen, Martin H.
    Bojer, Annemie S.
    Jorgensen, Niklas R.
    Broadbent, David A.
    Plein, Sven
    Madsen, Per L.
    Gaede, Peter
    [J]. CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)